# US 2025/0243252 A1 · Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0243252 A1
- Document ID: US20250243252A1
- Status: Published application
- Kind: A1
- Application number: 18/974,616
- Filed: 2024-12-09
- Published: 2025-07-31
- Earliest claimed: 2016-08-01
- Assignees: Virogin Biotech Canada Ltd
- Applicants: Virogin Biotech Canada Ltd.
- Inventors: William Jia; Guoyu Liu; Erica Lee; Dmitry Chouljenko; Jun Ding
- Web page: https://patentgrep.com/patent/US20250243252A1

## CPC

- C07K 14/5443: {IL-15}
- A61K 35/763: Herpes virus
- A61P 35/00: Antineoplastic agents
- C07K 14/035: Herpes simplex virus I or II
- C07K 14/5434: {IL-12}
- C07K 14/7155: {for interleukins [IL]}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/625: {containing a sequence coding for a signal sequence}
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 15/8695: {Herpes simplex virus-based vectors}
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

## Claims

### Claim 1

An HSV vector comprising an expression cassette for IL12, IL15, and IL15Receptor alpha subunit.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The HSV vector of claim 1, where the IL15 and IL15Receptor alpha subunit are co-expressed using a IRES sequence.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The HSV vector of claim 1 wherein the bi-directional promoter is bi-CMV.

### Claim 8 (depends on 1)

The HSV vector of claim 1, wherein each of the IL15 and IL15Receptor alpha subunit is followed by a nucleic acid sequence encoding Lys5 or Glu5.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The HSV vector of claim 1, further comprising an expression cassette for one or more PD-L1 blocking peptides.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The HSV vector of claim 10, further comprising one or more IRES sequences between multiple PD-L1 blocking peptides.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 10)

The HSV vector of claim 10, wherein the sequence encoding PD-L1 blocking peptides is inserted in between UL3 and UL4 viral genes.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The HSV vector of claim 1, wherein the expression cassette comprises at least one bidirectional CMV promoter.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The HSV vector of claim 1, wherein the expression cassette for IL12/IL15/IL15Receptor alpha subunit is inserted into either the internal repeat region or the terminal repeat region where the original viral sequence is replaced by the cassette.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A pharmaceutical composition, comprising a HSV vector according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 23)

A method of enhancing the efficacy of an immune response, comprising administering a pharmaceutical composition according to claim 23 to a patient having cancer.

### Claim 27 (depends on 26)

The method according to claim 26 wherein said cancer is selected from the group consisting of carcinomas, leukemia's, lymphomas, myelomas and sarcomas.

### Claim 28 (depends on 26)

The method according to claim 26 wherein said cancer is a melanoma.

### Claim 29 (depends on 26)

The method according to claim 26 wherein said cancer is a blastoma.

### Claim 30 (depends on 29)

The method according to claim 29 wherein said blastoma is selected from the group consisting of glioblastomas, medulloblastomas and retinoblastomas.

### Claim 31 (depends on 26)

The method according to claim 26 wherein said cancer is selected from the group consisting of bile duct cancer, breast, cervix, colorectal, acoustic neuroma, astrocytoma, craniopharyogioma, ependymoma, glioblastoma, hemangioblastoma, menangioma, neuroblastoma, oligodendroglioma, pinealoma, endometrial lining, kidney, larynx, lung, liver, oral cavity, ovaries, pancreas, prostate, squamous cell carcinoma and thyroid.
